In most people's minds, the first thing that comes to mind when they encounter the term "diabetes" is the sugar that is responsible for the disease. Having
Hyperopia Market Expected to Climb Moderately at a 1 0% CAGR During the Study Period [2018-2030], Analyses DelveInsight prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
reMYND extends Series B funding to EUR 24 million
reMYNDJanuary 21, 2021 GMT
reMYND extends Series B funding to EUR 24 million
Financing enables advancement of key programs in Alzheimer’s and Diabetes through Clinical Proof of Concept in 2022
Additional EUR 12 million raised
Leuven Belgium, 21 January 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, has successfully extended its Series B financing round to EUR 24 million. The second close of EUR 12 million by a consortium of investors including Korys Investments, FPIM, KU Leuven, PMV, and BNP Paribas Fortis Private Equity follows an initial EUR 12 million raised in December 2018.